Dr. Martens plc (LON:DOCS – Get Free Report)’s share price shot up 2.2% during trading on Wednesday . The company traded as high as GBX 73.65 ($0.91) and last traded at GBX 73.26 ($0.91). 2,724,084 shares traded hands during trading, an increase of 40% from the average session volume of 1,941,423 shares. The stock had previously closed at GBX 71.65 ($0.89).
Dr. Martens Trading Down 2.2 %
The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 129.55. The firm has a 50-day moving average of GBX 72.11 and a two-hundred day moving average of GBX 65.58. The firm has a market capitalization of £703.78 million, a P/E ratio of 1,045.41, a P/E/G ratio of 6.40 and a beta of 0.11.
Dr. Martens (LON:DOCS – Get Free Report) last posted its earnings results on Thursday, November 28th. The company reported GBX (1.30) (($0.02)) earnings per share for the quarter. Dr. Martens had a return on equity of 17.92% and a net margin of 7.89%. On average, analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current year.
Dr. Martens Cuts Dividend
Dr. Martens Company Profile
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Further Reading
- Five stocks we like better than Dr. Martens
- How to Use the MarketBeat Stock Screener
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- What Are Dividend Champions? How to Invest in the Champions
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.